Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial

Journal of Clinical Oncology

Volumn 27, Issue 23, 2009, Pages 3842-3848

  Steensma, David P ^a   Baer, Maria R ^a   Slack, James L ^a   Buckstein, Rena ^a   Godley, Lucy A ^a   Garcia Manero, Guillermo ^a   Albitar, Maher ^a   Larsen, Julie S ^a   Arora, Sujata ^a   Cullen, Michael T ^a   Kantarjian, Hagop ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CHILL; CLINICAL TRIAL; CONSTIPATION; CYTOGENETICS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SUBDURAL HEMATOMA; SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; OUTPATIENT; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OUTPATIENTS; TREATMENT OUTCOME;

EID: 68949145132     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6550     Document Type: Article

References (15)

1. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, V. 4:2006. National Comprehensive Cancer Network, 2006. http://www.nccn.org
2. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 134: 573-586, 2001
3. Leone G, Teofili L, Voso MT, et al: DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 87:1324-1341, 2002
4. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93, 1980
5. Pinto A, Zagonel V: 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends. Leukemia 7:51-60, 1993 (suppl 1)
6. Wijermans PW, Lubbert M, Verhoef G, et al: An epigenetic approach to the treatment of advanced MDS: The experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 84:9-17, 2005 (suppl 13)
7. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
8. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
9. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007
10. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425, 2006
11. Aribi A, Borthakur G, Ravandi F, et al: Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109:713-717, 2007
12. Wijermans PW, Ruter B, Baer MR, et al: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 34:587-591, 2008
13. Rüter B, Wijermans PW, Lubbert M: Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 106:1744-1750, 2006
14. Bow EJ, Laverdiere M, Lussier N, et al: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 94: 3230-3246, 2002
15. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109: 265-273, 2007